To reduce the incidence of severe neonatal hyperbilirubinemia affecting newborns with jaundice in the United States and to prevent kernicterus, there is a need to implement proven prevention strategies for severe neonatal hyperbilirubinemia as recommended in the 2004 American Academy of Pediatrics Guidelines for newborns >35 weeks gestational age. The purpose of universal predischarge bilirubin screening is to identify infants with bilirubin levels >75th percentile for age in hours and track those with rapid rates of bilirubin rise (>0.2 mg per 100 ml per h). Early identification has been reported to predict severe hyperbilirubinemia and allow for evidence-based targeted interventions. A systems approach is likely to reduce the preventable causes of acute bilirubin encephalopathy. To do so, highest priority should be given to (i) designating extreme hyperbilirubinemia (total serum bilirubin >427 mmol l À1 or >25 mg per 100 ml) as a reportable condition by laboratories and health-care providers through public health mandates; (ii) implementation of Joint Commission's Sentinel Report for kernicterus; (iii) nursing outreach to communities for education of prospective parents; (iv) development of clinical pathways to monitor, evaluate and track infants with extreme hyperbilirubinemia; and (v) societal awareness. These efforts should be monitored by a state and national surveillance system in order to critically improve the timeliness and completeness of notifications and to allow evaluation and interventions at the policy and individual family level.
Introduction
Postnatal hyperbilirubinemia is universal and manifests as newborn jaundice in over 80% of all newborns in the United States. Usually, bilirubin levels increase soon after birth and generally follow their hour-specific percentile track, remain within their risk zones and decline by the end of the first week. However, in some, rate of rise for bilirubin levels either continues or accelerates. Thus, unmonitored and untreated severe hyperbilirubinemia may progress to excessive levels that are likely to be associated with evident bilirubin neurotoxicity ( Table 1 ). The purpose of this review is to promote universal predischarge bilirubin screening in order to identify infants with bilirubin levels >75th percentile for age in hours and track those with rapid rates of bilirubin rise (>0.2 mg per 100 ml per h). Early identification has been reported to predict severe hyperbilirubinemia and allow for evidence-based targeted interventions. A systems approach is likely to reduce the preventable causes of acute bilirubin encephalopathy (ABE).
Background review
Kernicterus, a preventable form of neonatal bilirubin-related brain injury, is currently occurring in the United States and is a matter of public and societal concern.
1,2 The injury usually manifests as irreversible posticteric sequelae; the hallmark sign, usually at autopsy, is the icteric (yellow) staining of the basal ganglia, specifically the globus pallidus. With current technology it can be evidenced at that location as increased signals on magnetic resonance image. Injury occurs when the total serum bilirubin (TSB) level exceeds the infant's neuroprotective defenses and results in neuronal damage, primarily in the basal ganglia, central and peripheral auditory pathways, hippocampus, diencephalon, subthalamic nuclei, midbrain, pontine and brain stem nuclei for oculomotor function, respiratory, neurohumoral and electrolyte control and in the cerebellum, most prominently in the vermis.
comorbidities. [5] [6] [7] The term kernicterus is now usually reserved for irreversible classic sequelae diagnosed in infants who survive ABE and are diagnosed primarily as dystonia, athetoid cerebral palsy, paralysis of upward gaze and sensorineural hearing loss of varying degrees of severity. Cognition is usually spared to a striking degree. Bilirubin-induced neurologic dysfunction is a wider spectrum of disorders that includes classic kernicterus and ABE, but also clinical evidence of damage confined to more narrow neural pathways resulting in isolated, less severe forms of auditory neuropathy (auditory dys-synchrony) defined by characteristic clinical criteria and distinctive findings on the auditory brainstem evoked response without severe hearing loss or by similar auditory neuropathy associated with minimal fine and/or gross motor disability. 7 Although not yet proven, some experts believe that there may be still more subtle neurological manifestations of bilirubininduced neurologic dysfunction with only signs of awkwardness, minimal fine and gross motor incoordination and gait abnormalities, fine tremors, exaggerated extrapyramidal reflexes 8 and perhaps learning and behavioral problems. These subtle signs are difficult to diagnose because of delayed clinical expression and nonspecificity, but are important to look for as possible sequelae of ABE which need educational or occupational intervention. Clinical predisposition to bilirubin-induced neurologic dysfunction includes prematurity, rapid rate of bilirubin rise (usually associated with hemolysis), asphyxia, sepsis, hypoalbuminemia, lethargy and temperature instability. 1 Bilirubin screening A range of TSB levels, rather than a specific level, is the threshold for onset of neurotoxicity. 9 Bilirubin neurotoxicity is likely to occur when bilirubin moves from the circulation into the brain in increased quantities. There is strong evidence that bilirubin not bound to the single very high-affinity albumin-binding site, to less strong secondary albumin binding sites, or to binding sites on RBC's and lipoproteins is the toxic bilirubin moiety and a better predictor of neuronal damage than TSB. TSB consists of an overwhelmingly bound component in dynamic equilibrium with a tiny unbound fraction, present in nanomolar concentrations. Below saturation of the high-affinity albumin bonding site, when TSB levels remain below the 1:1 molar ratio of bilirubin to albumin and/or when there is no compromise of this binding site by illness, immaturity, postnatal age or by competing anions, circulating concentrations of the highly toxic unbound fraction remain below the threshold of the baby' defense mechanisms. Above saturation of this primary binding site, nanomolar concentrations of unbound bilirubin rise high enough to cause damage. 10 Because of these interrelationships, the risk of neurotoxicity may be interdependent on the levels of free bilirubin and/or TSB. It is in this context that universal predischarge screening, combined with assessment of gestational age, is most predictive of the risk of subsequent severe hyperbilirubinemia at age >72 h during the first week to 10 days after birth when timely intervention should be implemented efficiently because of a narrow safety margin.
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Biological risk factors Jaundice is the most common clinical diagnosis in neonatal medicine and is due to elevated unconjugated (indirect) and/or conjugated (direct) bilirubin levels. Confirmation is by a total serum (plasma) blood test for bilirubin (TSB) or transcutaneous bilirubin (TcB). Bilirubin is a known antioxidant at low levels (in vitro) and a potent neurotoxin at high levels (in vitro and in vivo). Elevated bilirubin concentrations may occur due to increased bilirubin production (breakdown of heme moiety of hemoglobin) and/or delayed bilirubin elimination (hepatic and intestinal) as well as by a unique neonatal phenomenon of enterohepatic reabsorption of bilirubin. Bilirubin and carbon monoxide are the major degradation products of heme. The non-water soluble unconjugated bilirubin (bound to albumin) is processed in the hepatocyte to the water-soluble conjugated bilirubin by the enzyme uridine-di-phospho-glucuronosyltransferase and excreted into the gut where some of the conjugated bilirubin is reconverted to unconjugated bilirubin and resorbed into the circulation (enterohepatic circulation). The low volume of oral intake, and caloric deprivation increase resorption of bilirubin and is further aggravated by decreased gastrointestinal activity characteristic of the early postnatal period. As noted above, the neurotoxic effect of bilirubin does not correlate well with TSB levels because it is influenced by the near-complete binding of bilirubin by albumin (g per 100 ml). Below a mg to gram bilirubin to albumin ratio of about 8:1 (approximately 1:1 on a molar basis), all bilirubin is bound at the first high-affinity binding site and is in equilibrium with so tiny a free fraction that concentrations of unbound bilirubin remain below the toxic level (Table 2) . However, these ratios do not apply when binding at the Neonatal jaundice and hyperbilirubinemia occur more commonly and are more prolonged among late preterm infants than full-term infants. 13, 14 Late preterm infants have overall less mature liver function, decreased activity of uridine diphosphoglucuronate glucuronosyltransferase for bilirubin conjugation, immature gastrointestinal function and more frequent feeding difficulties, especially if exclusively breastfed, which predispose them to dehydration, increased enterohepatic circulation, decreased stool frequency and hyperbilirubinemia. Glucose-6-phosphate dehydrogenase deficiency is also associated with a higher incidence of excessive neonatal hyperbilirubinemia and risk of kernicterus, especially if associated with Gilbert's disease or similar polymorphisms that diminish hepatic bilirubin conjugation or uptake. In most babies with glucose-6-phosphate dehydrogenase deficiency, slightly increased bilirubin production coupled with concurrent diminished bilirubin conjugation is the likely basis for severe hyperbilirubinemia. 14, 15 Exacerbation by a triggered increase in bilirubin production (such as exposure, often unpredictable, to known and unknown oxidants, infections and drugs that compete for albumin binding) may lead to progressive or hazardous hyperbilirubinemia. 16, 17 Clinical approach Clinicians have questioned whether predischarge screening for severe neonatal hyperbilirubinemia is predictive enough to allow successful implementation of timely interventions (use of phototherapy, exchange transfusion, chemoprevention). The assertion that infants with severe neonatal hyperbilirubinemia are at higher risk for acute or chronic bilirubin encephalopathy has been a longstanding clinical belief, which, however, has not been proven by rigorous clinical trials. With current clinical and research methodologies, such trials would be prohibitively expensive, and, because of the availability of phototherapy, ethically untenable. In this article, we review the current clinical methodologies to screen for risk of severe neonatal hyperbilirubinemia and/or need for interventions with phototherapy. Case reports of kernicterus are unusual and rarely identified in healthy infants when TSB levels are <25 mg per 100 ml (427 mmol l À1 ), and none have been reported for infants with known peak TSB levels <20 mg per 100 ml (342 mmol l À1 ) ( Table 1) . In one report, infants with ABE who presented with TSB levels >35 mg per 100 ml (598 mmol l À1 ) sustained some degree of posticteric sequelae regardless of treatment. 2 On the other hand, not all infants with TSB levels >30 mg per 100 ml (513 mmol l À1 ) manifest classic kernicterus. [18] [19] [20] Vulnerability to chronic sequelae, in infants with TSB levels between 20 and 35 mg per 100 ml, is influenced by postnatal age, rate of TSB rise, duration of extreme hyperbilirubinemia, late prematurity (<37 weeks), gender (male), being large for gestational age, dehydration (>15% weight loss over birth weight) and infection that is often associated with genetic abnormalities. 2 In an analogy to aviation safety standards, acute kernicterus events are akin to airline crashes.
Screening methodology
There is adequate evidence that screening using hour-specific bilirubin measurement and/or clinical risk factors can identify infants who are likely to develop severe neonatal hyperbilirubinemia. 1, 10 However, there is no known screening test that will identify infants at risk of developing chronic bilirubin encephalopathy. 21 Screening tests for hyperbilirubinemia consists of clinical risk assessment, measuring bilirubin level (either in plasma or by transcutaneous estimation), or a combination of methods. 1 Phototherapy is commonly used to treat severe neonatal hyperbilirubinemia. 1 A recent systematic review 22 reported that one needs to treat six to ten otherwise healthy jaundiced neonates with TSB X15 mg per 100 ml (X257 mmol l À1 ) with phototherapy in order to prevent the TSB in one additional infant from rising above 20 mg per 100 ml (342 mmol l
À1
). Exchange transfusion is used to treat ABE or extreme hyperbilirubinemia that is unresponsive to effective phototherapy. 1 With early detection and early intervention, the number of infants with severe hyperbilirubinemia is likely to decrease. 23, 24 However, the ability of phototherapy to prevent chronic bilirubin encephalopathy is not proven. Phototherapy has been safe, effective and associated with a declining need for exchange transfusions. 25 On the other hand, harms of detection and early treatment of hyperbilirubinemia could include potential unknown side effects of phototherapy and possible adverse events related to exchange transfusion. The extreme rarity of chronic bilirubin encephalopathy makes it nearly impossible to design and conduct a study that could directly evaluate the effectiveness of an intervention to reduce the incidence of this condition. As a result, intermediate outcomes such as bilirubin levels, severe neonatal hyperbilirubinemia (adjusted for postnatal age in hours, gestational age and hemolysis) are used. 1 
Screening tests
What is the purpose of the test? Predischarge bilirubin screening (age 18 to 48 h) identifies infants with bilirubin levels >75th percentile for age in hours and tracks those with rapid rates of bilirubin rise (>0.2 mg per 100 ml per h). Clinical recommendations for predictive risk assessment aim to reduce the incidence of severe hyperbilirubinemia and bilirubin encephalopathies, while minimizing the risks of unintended harm such as decreased breastfeeding, undue parental anxiety and unnecessary treatment. Clinical tests address the need for (i) recognition of early-onset hyperbilirubinemia, usually due to intra-vascular hemolysis caused by hemolytic disorders such as isoimmunization, neonatal red blood cell or enzymes disorders, or extra-vascular hemolysis (bruises and hematomas) and (ii) predictive predischarge risk assessment for late-onset hyperbilirubinemia related to late prematurity, weight loss, exclusive breastfeeding, movement of bilirubin into the circulation from large cephalhematomas, and possible slower than average maturation of liver conjugation and excretory functions that decrease the bilirubin rate of rise.
The nature of the tests. Assessment of risk factors: Clinical risk factors for severe neonatal hyperbilirubinemia [26] [27] [28] include exclusive and insufficient breast milk transfer, family history of neonatal jaundice, bruising, repeated attempts at vacuum extraction, cephalhematoma, ethnicity (Asian), maternal age (>25 years), male gender and gestational age <38 weeks (summarized in Table 3 ). The contribution of these risk factors to chronic bilirubin encephalopathy in healthy children is not well understood. Current literature reports that combining clinical risk factors with bilirubin levels can be useful in predicting later significant or severe hyperbilirubinemia. 29, 30 The predischarge bilirubin level, expressed as a risk zone on the bilirubin nomogram and used alone or when combined with multiple clinical risk factors had similar accuracy for predicting significant hyperbilirubinemia. In one single-center study, an infant's gestational age improved the overall predictive accuracy of predischarge bilirubin risk zone. 30 Visual assessment of jaundice. All infants should be routinely monitored for the development of jaundice, and nurseries should have established protocols for the assessment of jaundice. Jaundice should be assessed whenever the infant's vital signs are measured, but no less than every 8 to 12 h. Jaundice can be detected by blanching the skin with digital pressure on the forehead, midsternum or the knee/ankle to reveal the underlying color of the skin and subcutaneous tissue. 1, 31 Jaundice is usually seen first in the face and progresses caudally to the trunk and extremities, but can sometimes appear and fade, similar to a tan. It may be helpful to adjust for intensity of color (lemon or orange) as well as corroborate the progression of jaundice with a TcB value 32 ( Figure 1 ). The assessment of jaundice must be performed in a well-lit room or, preferably, in daylight at a window. Absence of jaundice is not an indication of absence of hyperbilirubinemia; estimating the degree of hyperbilirubinemia can lead to errors and the apparent absence or severity of jaundice may not predict subsequent severe hyperbilirubinemia. [31] [32] [33] Before 72 h age (prior to discharge) and particularly at less than 24 h age, presence of clinical jaundice needs to be corroborated by a bilirubin measurement (TSB or TcB). In a recent study, 34 nurses' predischarge assessment of jaundice extent was only moderately correlated with bilirubin concentration and was similar in black and non-black infants. The correlation was particularly weak among late preterm infants. Jaundice extent had poor overall accuracy for predicting risk of significant hyperbilirubinemia (c-statistic ¼ 0.65), but complete absence of jaundice had high sensitivity (95%) and negative predictive value (99%) for ruling out the development of significant hyperbilirubinemia. Currently, clinicians should not solely rely on cephalo-caudal jaundice progression to estimate bilirubin levels during the birth hospitalization, or to predict subsequent severe neonatal hyperbilirubinemia. However, the complete absence of jaundice (when reliably recognized) may predict infants will not develop significant hyperbilirubinemia.
Bilirubin measurement: The strategies recommended for predischarge assessment are screening by a TSB/TcB measurement plotted on an hour-specific nomogram that identifies risk zones, and/or assessment of clinical risk factors. 1, 11 The nomogram provides a more appropriate understanding of the magnitude of hyperbilirubinemia in the contexts of postnatal age in hours and the percentile level as defined for healthy infants. 35 It is important to note that infants with early-onset extreme hyperbilirubinemia that required intervention before age <48 h were not included in the predictive nomogram because treatment with phototherapy and/ or exchange transfusion had already been instituted. TSB and TcB are the only currently available clinical tests that can be used to predict the risk of subsequent severe hyperbilirubinemia when these values are plotted on an hour-specific nomogram (Figure 2 ). When measured concurrent to the routine predischarge metabolic screening and plotted on the hour-specific nomogram in lieu of using day-specific values, TSB is a powerful and significant screening tool in term and late preterm babies (Figure 2 ). It defines the high risk and low risk for post-discharge excessive hyperbilirubinemia. The predictive accuracy and the significance of its role as a useful and practical screening tool are shown in the receiver operating curve for TSB (Figure 3) . The clinical significance of these data is not only the identification of a high-risk population but also that of the low-risk population. The predictive ability of TSB has now been validated by several other prospective studies. 11, 21 Recent data indicate that at least one major clinical analyzer provided inaccurate bilirubin values for Neonatal Bilirubin Survey specimens administered by the College of American Pathologists. Use of human serum-based survey specimens to calibrate bilirubin testing is likely to reduce system error and yield a substantial improvement in bilirubin measurements. 36 TcB testing is a potentially accurate and non-invasive alternative to TSB measurement. 11,37 -40 TcB devices are useful screening tools and provide a valid estimate of the TSB level, although data are limited. TcB levels can be unreliable during phototherapy or with exposure to sunlight because of the bleaching effect of light on the skin. Confounding effects of skin melanin content among different races, and manufacturing inconsistencies among devices are additional limitations. More recently, the BiliCheck device (Phillips-Respironics, Murraysville, PA, USA) and the JM-103 device (Konica Minolta/Air-Shields JM-103 Jaundice Meter from Drager Medical, Telford, PA, USA) have overcome earlier limitations of traditional devices by correcting for skin melanin content. These new devices can provide accurate and reproducible measurements comparable with clinical laboratory tests for serum samples. Measurements in newborns using the new TcB devices are within 2 to 3 mg per 100 ml (34 to 51 mmol l À1 ) of the TSB and useful for TSB levels <15 mg per 100 ml (257 mmol l À1 ). The accuracy and precision of TcB assays >15 mg per 100 ml is unproven because of erratic performance at higher bilirubin levels in comparison to laboratory assay of TSB. Figure 1 Modified Kramer scale to assess and plot progression of newborn jaundice according to demarcated skin zones and intensity of color as correlated to transcutaneous bilirubin (TcB) levels (adapted from Maisels and Kring 38 ). This figure describes the cephalo-caudal progression of jaundice in term infants. Jaundice usually starts on the head and extends toward the feet as the level rises. This is useful in deciding whether or not a baby needs to have the TcB and, possibly, the total serum bilirubin measured. For documentation five zones are defined on the infant (see figure) . The TcB level associated with progression to the zones can be charted.
Screening strategy
Practical decision analysis in the clinical setting is complicated by variability in bilirubin measurements attributed to laboratory and sampling methodologies and uncertainty regarding threshold TSB/ TcB values that can be considered as safe. By expressing TSB values in terms of risk zones, rather than using an actual TSB value, the imprecision of TSB measurement is reduced and the low-risk zone is possibly a safe zone for term and healthy neonates.
Use of hour-specific bilirubin nomogram to guide follow-up
The primary purpose of the bilirubin nomogram is to provide a simple and accurate method for quantifying the risk that a newborn will develop hyperbilirubinemia, requiring treatment after discharge from the nursery. We recommend that infants in the low-risk zone, particularly those discharged from the hospital before 72 h of life and breastfed, be seen by a health-care provider (office or home visit) on days 4 to 5 of life to evaluate their nutritional status (hydration, weight loss, breastfeeding) and to observe for obvious jaundice. Table 4 charts a bilirubin care map for designating follow-up for a repeat test based on the predischarge bilirubin risk zone.
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What does an abnormal test result mean? The hour-specific bilirubin nomogram serves as a useful clinical guide for management because the patterns of severity in mg per 100 ml are at or above the 75th percentile for age in hours. The high-risk zones define the threshold for which interventions and recommendations for vigilant follow-up are indicated in the diverse US population. Infants with repeat bilirubin levels allows clinicians to track those who are likely to cross into higher-risk zones with Figure 2 An approach for a timed follow-up to repeat jaundice and bilirubin evaluation based on predischarge bilirubin testing by plotting TSB or TcB (<15 mg per 100 ml) on an hour-specific bilirubin nomogram A TcB >15 mg per 100 ml needs confirmation by laboratory TSB assay. Infants with early-onset extreme hyperbilirubinemia requiring intervention <48 h were not included in the predictive nomogram because treatment with phototherapy and/or exchange transfusion had already been instituted (adapted from Kaplan et al. 16 ). TcB, transcutaneous bilirubin; TSB, total serum bilirubin. accelerated rates of bilirubin rise (>0.2 mg per 100 ml per h). This nomogram was not specifically designed to be used in premature infants (<35 weeks gestational age) or infants with comorbidities requiring intensive neonatal care. These infants, who are not considered healthy, are at higher risk of developing bilirubin toxicity and of developing kernicterus at lower bilirubin levels. In term or near-term infants, the nomogram is helpful in identifying infants who have early hyperbilirubinemia (those in the high-risk zone or with a rapid rate of rise) and who require further evaluation for a cause of their hyperbilirubinemia. Once it is known that an infant has hemolysis due to conditions such as: ABO, Rh or minor blood type incompatibility, or glucose-6-phospho-dehydrogenase deficiency, the nomogram is useful to track the progression and resolution of hyperbilirubinemia.
What does a normal test result mean?
Infants with TSB or TcB values at less than 40th percentile for age in hours are designated as a low-risk group. These infants may then be followed less intensively but according to routine recommendations to allow for efficient targeting of services and allocation of resources. More importantly, the families can be reassured that they are most likely to have a safe experience with newborn jaundice. Late preterm infants who have TSB/TcB <40th percentile should be followed because of possible delayed onset of severe hyperbilirubinemia (Table 4) .
Predischarge management
A systems-based approach in well baby nurseries can address parental education, clinical recognition of jaundice and predischarge risk assessment with multidisciplinary strategies as listed in Tables 3 and 4 .
Post-discharge follow-up management A seamless continuation of care should provide the following services: (a) ensuring the arrangement of and compliance with outpatient follow-up appointments; (b) training of personnel to handle outpatient phone calls for assessment of a symptomatic jaundiced newborn; (c) rapid Emergency Room/office intervention plans to transfer a symptomatic neonate to a neonatal intensive care facility; and (d) expeditious and timely intervention with the appropriate and effective bilirubin reduction strategies. If appropriate follow-up cannot be ensured in the presence of elevated risk for developing severe hyperbilirubinemia, it may be necessary to delay discharge until either appropriate follow-up can be ensured or the period of greatest risk has passed.
Decision support tools
In order to facilitate a systems-based approach to testing, predischarge management, and follow-up, an electronic, web-based clinical decision support tool has been developed. This free web application, known as BiliTool (Bilitool, Palo Alto, CA, USA), uses age and TSB data to automatically produce recommendations for monitoring, follow-up and treatment. 42 The recommendations are based on the existing hour-specific hyperbilirubinemia risk nomogram, AAP phototherapy guidelines and the California Perinatal Quality Care Collaborative's Severe Hyperbilirubinemia Prevention Toolkit. 43 BiliTool aims to make risk assessment and care more reliable by automating and simplifying the plotting process and providing a framework to systematize treatment and follow-up care.
Accuracy of screening tests to predict need for treatment
No studies have directly addressed whether screening with risk factor assessments or bilirubin testing reduces the incidence of chronic bilirubin encephalopathy. Overall, screening by individual or combined use of clinical risk factors, TcB, or TSB measurements is effective in predicting a subsequent high bilirubin level. Only two risk factors have been consistently identified: exclusive breastfeeding (with poor milk transfer) and younger gestational age. These have yet to be independently validated in diverse populations. There are no current studies that directly address (Figure 2 ). whether identification of infants by routine bilirubin testing predicts the need for phototherapy. Descriptive uncontrolled observations suggest that screening is associated with increased diagnoses of hyperbilirubinemia and fewer readmissions for hyperbilirubinemia. Of these, infants with TcB measurements less than the 75th hour-specific percentile in one study and below the 90th hour-specific percentile in another study did not reach TSB measurements that necessitated the use of phototherapy.
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Discussion
Of the over 4 million infants born each year in the United States, nearly 3.5 million are over 35 weeks in gestation and should have benign outcomes with little or no threat of neurological compromise during the first year after their birth. Most are discharged from their birth hospital before 72 h of age, before the usual peak of TSB occurring at age 72 to 120 h, their jaundice usually resolves by age 7 to 10 days, and the outcome is benign. However, significant hyperbilirubinemia (>95th percentile for age in hours) occurs in 8 to 11% of infants with approximately 2 to 5% requiring readmission to a hospital for treatment. 35 The exact incidence of chronic bilirubin encephalopathy is not known or surveyed, but should be exceedingly rare with current clinical practice. In one study, 2 125 cases were documented in the voluntarily reported Pilot USA Kernicterus Registry for term and late preterm infants during the period from 1992 to 2004. Approximately 1 in 650 to 1000 infants >35 weeks of gestation can develop serum bilirubin values of >25 mg per 100 ml (>427 mmol l
À1
) and approximately 1 in 10 000 have levels of >30 mg per 100 ml (>513 mmol l À1 ). The frequency of catastrophic hyperbilirubinemia (TSB >513 mmol l À1 ) is listed in Table 1 . There is a varying occurrence of infants with total bilirubin levels >25 mg per 100 ml and incidence of chronic kernicterus from diverse communities and practices. In Denmark, there were no case reports of kernicterus in the 20 years before a report of eight cases between 1994 and 2002 (incidence of 1.4/ 100 000 live births). Between 2002 and 2005, with a more vigilant approach to newborn jaundice management, the overall incidence reduced to 1.1/100 000 live births between 1994 and 2005. 44 , 45 We have estimated that risk of kernicterus in infants with TSB >25 mg per 100 ml ranged from 1 in 14 to 16 to a risk range of 1 in 4 to 7 in infants with TSB >30 mg per 100 ml. None of the retrospective data provide any insight into signs of acute kernicterus in infants with TSB <25 mg per 100 ml. 46 
Cost of testing
The actual cost of a TSB measurement, when performed at metabolic screen, is due to the laboratory assay of an additional aliquot of a blood sample. This cost to the institution is usually less than a dollar. On the other hand, any additional heel-stick is dependent on individual institutional charge. Additional costs for TSB measurements are related to ensuring accuracy, as the reproducibility of this measurement in the clinical laboratory is occasionally erratic; this variability is attributed to problems with sampling, handling or assay methodology. To address such concerns about standardization, the College of American Pathologists conducts a Neonatal Bilirubin and a Chemistry survey every 4 months to provide each participating laboratory an assessment of its bilirubin calibration performance. 36 Costs for TcB measurements are the capital cost of the device ($2000 to $4000) and that for the disposable probes (for calibration and hygiene) at about $5. In order to recommend routine bilirubin testing for every newborn, performance standards are essential for measurements of both TSB and TcB devices that are calibrated to nationally acceptable standards. 36 On the basis of internal reviews, four major 'for-profit' healthcare organizations have voluntarily implemented universal predischarge bilirubin screening. 20 With a recent multihospital corporate program of universal screening, the incidence of infants with total bilirubin 25.0 to 29.9 mg per 100 ml declined from 43 per 100 000 to 27 per 100 000, and the incidence of infants with total bilirubin of >30.0 mg per 100 ml dropped from 9 per 100 000 to 3 per 100 000 live-births. 47 This change was associated with a slight increase in phototherapy use. Public health cost effectiveness of universal bilirubin screening, either as an institutional program or a statewide public health endeavor, has not yet been determined. As some authors have asserted, implementation of a universal screening program would likely increase expenditures due to a greater volume of tests and follow-up visits. As kernicterus incidence and the likely relative risk reduction achieved by universal screening are unknown, an ideal cost-benefit analysis is elusive. However, in spite of those hurdles, one study, assuming an incidence of 1 out of 100 000 live births and a relative risk reduction of 70%, estimated the cost to prevent one case as approximately $5.7 million. 48 However, the actual incidence of kernicterus has now been reported as 1 in 38 000 live births. 49 Thus, accounting for this higher incidence and the savings in dollars for avoiding a lifetime of kernicterus (based on Centers for Disease Control and Prevention and other estimates that monetize the cost for a statistical child with cerebral palsy or mental retardation) net dollar savings are likely.
Need for effective implementation
Bilirubin-induced neurologic dysfunction can occur in term and late-preterm healthy babies, but can be effectively prevented by rapid reduction of the increased bilirubin load by intensive phototherapy and/or exchange transfusion. However, these interventions leave a very narrow margin of safety for babies who are usually at home and not under direct medical supervision at the natural peak of hyperbilirubinemia (age 3 to 5 days). To ensure a safe experience with newborn jaundice and to efficiently prevent severe hyperbilirubinemia such that the full spectrum of bilirubin-related toxicities (including kernicterus) may be prevented, every infant should be screened by a systematic assessment for the risk of severe hyperbilirubinemia by both clinical and TSB/TcB screening with targeted close follow-up based on the hour-specific bilirubin nomogram to identify infants in need of prompt intervention for significant neonatal hyperbilirubinemia. Effective monitoring of compliance with these recommendations is essential but difficult. The most readily achievable strategy would be oversight of laboratory reporting of the occurrence of TSB levels over 427 mmol l À1 (25 mg per 100 ml). Instances of such extreme hyperbilirubinemia represent failure of the proposed systems approach to jaundice management in achieving its most rigorous goalFprevention of near miss and potential 'never events'Fand provides a body of data to estimate its ability to improve medical care in a cost-effective way and identify medical and societal reasons for their occurrence.
A family centered, systems-based approach that builds constructive parent/health-care partnerships aimed at the prevention of a spectrum of bilirubin toxicity and related disabilities are incorporated in the 2004 American Academy of Pediatrics guidelines 1 and made available through the Centers for Disease Control and Prevention website: http://www.cdc.gov/ ncbddd/dd/kernichome.htm. Strategies to implement and institutionalize the evidence-based and consensus-driven guidelines for safer management of newborn jaundice are needed and should be complemented with practice-based surveillance of the use of phototherapy and incidence of near-miss events. 41, 42 Conclusion Universal screening combined with the clinical risk factors (of which gestational age is the most significant) is a key component of the systems approach that has been implemented in several birthing facilities and health-care organizations in the United States of America. This breakthrough systems approach provides a method of identifying infants who are at high risk or low risk for the development of severe neonatal hyperbilirubinemia. In addition to risk assessment, the measurement of the TSB or TcB when interpreted using the hour-specific nomogram provides the caregiver with one immediate and quantitative mechanism for assessing the degree of hyperbilirubinemia and the need for additional surveillance and testing. 11, 35 An online tool for riskassessment through http://www.bilitool.org allows for immediate clinician access and promotes a clinician-parent partnership for seamless continuity of care from the birthing hospital to home care. Through effective implementation and surveillance, universal bilirubin screening could prevent ABE and kernicterus.
